IL2 and metastatic melanoma: L19-IL2 is an immunocytokine featuring the L19 antibody fused to the cytokine IL2 payload, which is currently being investigated with encouraging results for the treatment of metastatic melanoma in phase II and phase III clinical trials, in combination with targeted TNF.